Press Releases July 15, 2026 04:15 PM

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

Certara to announce Q2 2026 financial results and host earnings call on August 4th, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CERT

Certara, Inc., a leader in model-informed drug development, will release its Q2 2026 financial results before market open on August 4th, 2026, followed by a management conference call. The company provides biosimulation and regulatory solutions to the global biopharmaceutical industry.

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
CERT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Certara specializes in model-informed drug development and regulatory science solutions.
  • The Q2 2026 financial results will be announced before market open on August 4, followed by a webcasted conference call.
  • Certara serves over 2,600 clients including biopharma companies and global regulatory agencies, impacting the biotech and pharmaceutical sectors.

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.

Investor Relations Contact:
Erik Abdow
Gilmartin Group
[email protected]

Media Contact:
Alyssa Horowitz
[email protected]


Risks

  • Financial performance may not meet investor expectations based on future results, causing potential stock volatility.
  • The regulatory and biopharmaceutical sectors can be affected by changes in drug development timelines or regulatory policies.
  • Market reaction depends on the details in the upcoming earnings report, which are currently unknown.

More from Press Releases

Record Revenue and Successful Mountain Commerce Bancorp Acquisition Drive Strong Second Quarter Results for HOMB Jul 15, 2026 Great Southern Bancorp, Inc. Reports Preliminary Second Quarter Earnings of $1.43 Per Diluted Common Share Jul 15, 2026 Xanadu to Report Second Quarter 2026 Financial Results on August 5th, 2026 Jul 15, 2026 Synaptics to Release Fourth Quarter and Full Year Fiscal 2026 Results on August 6, 2026 Jul 15, 2026 Eos Energy Enterprises Selected to Deliver Mission-Ready Power for Golden Dome for America Jul 15, 2026